open access

Vol 14, No 1 (2018)
Guidelines / Expert consensus
Published online: 2018-02-28
Get Citation

Management of extravasation of antineoplastic agents

Maryna Rubach
DOI: 10.5603/OCP.2018.0006
·
Oncol Clin Pract 2018;14(1):15-22.

open access

Vol 14, No 1 (2018)
GUIDELINES FOR DIAGNOSTIC AND THERAPEUTIC MANAGEMENT
Published online: 2018-02-28

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

chemotherpy, extravasation, cytotoxic drugs, cytostatic drugs

About this article
Title

Management of extravasation of antineoplastic agents

Journal

Oncology in Clinical Practice

Issue

Vol 14, No 1 (2018)

Article type

Guidelines / Expert consensus

Pages

15-22

Published online

2018-02-28

DOI

10.5603/OCP.2018.0006

Bibliographic record

Oncol Clin Pract 2018;14(1):15-22.

Keywords

chemotherpy
extravasation
cytotoxic drugs
cytostatic drugs

Authors

Maryna Rubach

References (21)
  1. Larson DL. Treatment of tissue extravasation by antitumor agents. Cancer. 1982; 49: 1796–1799.
  2. Langstein HN, Duman H, Seelig D, et al. Retrospective study of the management of chemotherapeutic extravasation injury. Ann Plast Surg. 2002; 49(4): 369–374.
  3. Pérez Fidalgo JA, García Fabregat L, Cervantes A, et al. ESMO Guidelines Working Group, ESMO Guidelines Working Group. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol. 2012; 23 Suppl 7(5): vii167–vii173.
  4. Cosciato DA, Lowitz BB. Extravasation of antitumor agent. Man Clin Oncol. ; 1995: 479–480.
  5. Unseld M. Extravasation of chemotherapy. ESMO Handbook of Oncological Emergencies. ; 2016: 58–68.
  6. Dutcher JP, Wiernik P. Nagłe przypadki w hematologii i onkologii. PZWL 1993.
  7. Rudolph R, Larson DL. Etiology and treatment of chemotherapeutic agent extravasation injuries: a review. J Clin Oncol. 1987; 5(7): 1116–1126.
  8. Dorr RT, Alberts DS. Failure of DMSO and vitamin E to prevent doxorubicin skin ulceration in the mouse. Cancer Treat Rep. 1983; 67(5): 499–501.
  9. Langer SW. Dextrazoxane in antracycline extravasation. J Clin Oncol. 2000; 18: 3064.
  10. Kretzschmar A. Extravasations of oxaliplatin. J. Clin. Oncol. 2003; 21(1): 4068.
  11. Bertelli G. Topical Dimethylsulfoxide for prevention of soft tissue injury after extravasation of vesicany cytotoxic drugs: a prospective clinical study. J Clin Oncol. 1995; 13: 2851–2855.
  12. Oliver IN. A prospective study of topical dimethylsulfoxide for treating anthracycline extravasation. J. Clin Oncol. 1988; 6: 1732–1735.
  13. Dorr RT. Antidotes to vesicant chemotherapy extravasation. Blood Rev. 1990; 4: 41–60.
  14. Schulmeister L. Managing vesicant extravasations. Oncologist. 2008; 13(3): 284–288.
  15. Schulmeister L. Extravasation management: clinical update. Semin Oncol Nurs. 2011; 27(1): 82–90.
  16. Albanell J, Baselga J. Systemic therapy emergencies. Semin Oncol. 2000; 27(3): 347–361.
  17. Schrijvers DL. Extravasation: a dreaded coplication of chemotherapy. Ann Oncol. 2003; 14(supl. 3): 26–30.
  18. Langer SW, Sehested M, Jensen P. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Annals of Oncology. 2001; 12(3): 405–410.
  19. Kosmidis PA, Schrijvers D, Andre F, et al. Extravasation of chemotherapy. ESMO Handbook of oncological emergencies. Taylor & Francis. ; 2005: 37–43.
  20. Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol. 2004; 15: 858–662.
  21. Kreidieh FY, Moukadem HA, El Saghir NS. Overview, prevention and management of chemotherapy extravasation. World J Clin Oncol. 2016; 7(1): 87–97.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl